The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1b trial of IFx-Hu2.0, a novel in situ cancer vaccine, in checkpoint inhibitor-resistant Merkel cell carcinoma (MCC) and cutaneous squamous cell carcinoma (cSCC).
 
Andrew Scott Brohl
Consulting or Advisory Role - Bayer; Deciphera
Expert Testimony - GlaxoSmithKline (I)
 
Ann W. Silk
Stock and Other Ownership Interests - Illumina
Consulting or Advisory Role - Merck; Natera; Regeneron
Research Funding - Checkmate Pharmaceuticals (Inst); Merck (Inst); Morphogenesis (Inst); Regeneron (Inst); Replimune (Inst); Shattuck Labs (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate
 
Jacob Stephen Thomas
Consulting or Advisory Role - Kura Oncology; Tasly Pharmaceuticals
 
Zeynep Eroglu
Consulting or Advisory Role - Incyte; Pfizer; Regeneron; Sun Pharma
Research Funding - Boehringer Ingelheim (Inst); Novartis (Inst); Pfizer (Inst)
 
Ahmad A. Tarhini
Consulting or Advisory Role - AstraZeneca; Bayer; BioNTech; Bristol-Myers Squibb; Clinigen Group; ConcertAI; Eisai; Genentech/Roche; Instil Bio; Merck; Nested; Novartis; Partner Therapeutics; Sanofi/Regeneron
Research Funding - Acrotech Biopharma (Inst); Agenus (Inst); Agenus (Inst); Bristol-Myers Squibb (Inst); Clinigen Group (Inst); Genentech/Roche (Inst); InflaRx (Inst); Merck (Inst); OncoSec (Inst); Pfizer (Inst); Sanofi/Regeneron (Inst); Scholar Rock (Inst)
 
Deanryan B. De-Aquino
No Relationships to Disclose
 
Edith Abraham
No Relationships to Disclose
 
Nikhil I. Khushalani
Stock and Other Ownership Interests - Amarin Corporation; Asensus Surgical; Bellicum Pharmaceuticals
Consulting or Advisory Role - Array BioPharma; AstraZeneca; Bristol-Myers Squibb; Castle Biosciences; Genzyme; Immunocore; Incyte; Instil Bio; Iovance Biotherapeutics; Jounce Therapeutics; Merck; NCCN/Pfizer; Nektar; Novartis; Regeneron; Replimune
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); GlaxoSmithKline (Inst); HUYA Bioscience International (Inst); Merck (Inst); Modulation Therapeutics (Inst); Novartis (Inst); Regeneron (Inst); Replimune (Inst)
Travel, Accommodations, Expenses - Castle Biosciences; Regeneron
Other Relationship - Bristol-Myers Squibb/Celgene; Nektar; Regeneron; Replimune; T-knife Therapeutics
 
Joseph Markowitz
Stock and Other Ownership Interests - Aflac; Amdocs; Consolidated Edison; CVS; Intel
Consulting or Advisory Role - Newlink Genetics
Research Funding - Idera (Inst); Merck (Inst); Morphogenesis (Inst)
Patents, Royalties, Other Intellectual Property - Patent on development of Inhibitors for S100B (Inst); Pending patent on flow cytometry analysis system (Inst); Pending patent on the role of nitric oxide in melanoma. (Inst)
Other Relationship - Springer
 
Kenneth Yee Tsai
Stock and Other Ownership Interests - Dimerix; NFlection Therapeutics
Consulting or Advisory Role - EMD Serono; NFLection Therapeutics; Sun Pharma; Verrica Pharmaceuticals; Voiant Clinical
Research Funding - FORMA Therapeutics
Patents, Royalties, Other Intellectual Property - NFlection Therapeutics and Moffitt Cancer Center, John Kincaid, Kavita Sarin, Kenneth Y. Tsai, ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS, 046776-523P01US, 11/20/2019; UCSB, Samir Mitragotri, Byeong Hee Hwang, Nishit Doshi, Kenneth Tsai, Russell M. Lebovitz. COMPOSITIONS FOR SOLUBILIZING CELLS AND/OR TISSUE, United States, 13/432,978, 3/28/2012.